Compare EEIQ & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | REVB |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 5.1M |
| IPO Year | 2021 | N/A |
| Metric | EEIQ | REVB |
|---|---|---|
| Price | $0.18 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 131.6K | ★ 1.9M |
| Earning Date | 01-28-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,939,989.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $0.15 | $1.41 |
| 52 Week High | $1.74 | $54.48 |
| Indicator | EEIQ | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 30.02 | 54.67 |
| Support Level | $0.15 | $1.43 |
| Resistance Level | $0.23 | $1.63 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 20.11 | 54.05 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).